Study on the application effect of Once VexGM-CSF and adriamycin in the interventional therapy of malignant tumor in clinical curative effect

National Medical Journal of China

Volumn 96, Issue 27, 2016, Pages 2173-2175

  Gao, Yundong ^a   Chen, Guangli ^a   Guo, Pengde ^a   Yang, Xinlei ^a  

^a BEIHUA UNIVERSITY   (China)

Author keywords

Neoplasms; Simplexvirus; Treatment outcome

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; DOXORUBICIN; TALIMOGENE LAHERPAREPVEC; TUMOR MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; ADENOVIRIDAE; NEOPLASM;

ADENOVIRIDAE; DOXORUBICIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS;

EID: 85016090043     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2016.27.013     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics [J]. CA Cancer J Clin, 2005, 55(2).-74-108. DOI:10.3322/canjclin.55.2.74.
2. Gatenby RA. A change of strategy in the war on cancer [J]. Nature, 2009, 459(7246):508-509. DOI:10.1038/459508a.
3. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3 (1)/SV40 T-antigen transgenic mice[J]. Cancer Res, 2005, 65(4): 1532-1540. DOI:10.1158/0008-5472. CAN-04-3353.
4. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain[J]. Gene Ther, 2005, 12 (8): 647-654. DOI:10.1038/sj.gt.3302445.
5. Zeng WG, Li JJ, Hu P, et al. An oncolytic herpes simplex virus vector, G47A, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep, 2013, 29 (6): 2355-2361. DOI:10.3892/or.2013.2359.
6. Qu W, Zhu Z, Zhao L, et al. Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy [J]. Int J Oncol, 2012, 41(6):2175-2183. DOI:10.3892/ijo.2012.1657.
7. Kanno T, Gotoh A, Nakano T, et al. Beneficial oncolytic effect of fiber-substituted conditionally replicating adenovirus on human lung cancer[J]. Anticancer Res, 2012, 32(11):4891-4895.
8. Grünwald GK, Klutz K, Willhauck MJ, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus [J]. Gene Ther, 2013, 20(6):625-633. DOI:10.1038/gt.2012.79.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours; revised RECIST guideline (versionl.l)[J].Eur J Cancer, 2009, 45 (2):228-247. DOI:10.1016/j.ejca.2008.10.026.
10. Gotoh A, Kanno T, Nagaya H, et al. Gene therapy using adenovirus against malignant mesothelioma [J]. Anticancer Res, 2012, 32 (9):3743-3747.
11. Jiang G, Zhang K, Jiang AJ, et al. A conditionally replicating adenovirus carrying interleukin-24 sensitizes melanoma cells to radiotherapy via apoptosis[J]. Mol Oncol, 2012, 6(4):383-391. DOI:10.1016/j.molonc.2012.05.001.
12. Nagaya H, Tagawa M, Hiwasa K, et al. Fiber-substituted conditionally replicating adenovirus for oncolysis of human renal carcinoma cells[J]. Anticancer Res, 2012, 32 (7):2985-2989.
13. Chen HY, dayman ES, Ma WF. Phenotypic knockout of CXCR4 expression by a novel intrakine mutant hSDF-1 α/54/KDEL inhibits breast cancer metastasis [J]. J Interferon Cytokine Res, 2015, 35(10):771-778. DOI:10.1089/jir.2014.0141.
14. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2003, 21(8):1498-1504. DOI:10.1200/JCO.2003.09.114.
15. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the ElB-55-kd-gene-deleted adenovirus ONYX-015 (dll520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer [J]. J Clin Oncol, 2002, 20(6):1562-1569. DOI:10.1200/JCO.20.6.1562.
16. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dll520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial [J]. Gene Ther, 2001, 8(21):1618-1626.
17. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer [J]. Clin Cancer Res, 2000, 6(3):798-806.